86499-35-6

Basic information

• Product Name: 3-Amino-2,3,4,5-Tetrahydro-1H-1-benzazepin-2-one
• Synonyms: 3-AMINO-2,3,4,5-TETRAHYDRO-1H-1-BENAZEPIN-2-ONE;3-AMINO-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-2-ONE HYDROCHLORIDE;3-AMINO-1,3,4,5-TETRAHYDRO-2H-1-BENZAZEPIN-2-ONE;3-AMINO-1,3,4,5-TETRAHYDRO-BENZO[B]AZEPIN-2-ONE;3-Amino-2,3,4,5-tetrahydro-2-oxo-2H-1-benzazepine;3-Amino-2,3,4,5-Tetrahydro-1H-1-benzazepin-2-one;Benazepril Intermediate;3-amino-1,3,4,5-tetrahydro-2H-benzaone-2-one
• CAS NO: 86499-35-6
• Molecular Formula: C₁₀H₁₂N₂O
• Molecular Weight: 176.22
• Product Categories: pharmacetical
• Mol File: 86499-35-6.mol

Chemical Properties

• Melting Point: 193-195 °C
• Boiling Point: 377.5 °C at 760 mmHg
• Flash Point: 182.1 °C
• Appearance: /
• Density: 1.143 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• PKA: 14.57±0.40(Predicted)
• CAS DataBase Reference: 3-Amino-2,3,4,5-Tetrahydro-1H-1-benzazepin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-2,3,4,5-Tetrahydro-1H-1-benzazepin-2-one(86499-35-6)
• EPA Substance Registry System: 3-Amino-2,3,4,5-Tetrahydro-1H-1-benzazepin-2-one(86499-35-6)

Safety Data

• Hazardous Substances Data: 86499-35-6(Hazardous Substances Data)

Usage

Synthesis Reference(s)

The Journal of Organic Chemistry, 50, p. 3408, 1985 DOI: 10.1021/jo00218a034

InChI:InChI=1/C10H12N2O.ClH/c11-8-6-5-7-3-1-2-4-9(7)12-10(8)13;/h1-4,8H,5-6,11H2,(H,12,13);1H

Upstream product

• 97278-68-7 3-azido-2,3,4,5-tetrahydro-2-oxo-1 H-1-benzazepine 
• 68253-36-1 1-tetralone oxime 
• 19832-98-5 4-methyl-3,4-dihydro-2H-naphthalen-1-one 
• 529-34-0 3,4-dihydronaphthalene-1(2H)-one 
• 86499-96-9 3-bromo-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one 
• 88372-41-2 (+/-)-2-amino-4-(2-amino-phenyl)-butyric acid 
• 7440-44-0 pyrographite 
• 7772-99-8 stannous chloride 
• 4424-80-0 2,3,4,5-tetrahydro-1H-1-benzo[b]azepin-2-one 
• 140700-64-7 3-iodo-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one 

Downstream Products

• 137036-55-6 (R)-3-amino-2,3,4,5-tetrahydro-1H-[1]-benzazepin-2-one 
• 137036-54-5 (S)-3-amino-2,3,4,5-tetrahydro-1H-[1]-benzazepin-2-one 
• 86499-69-6 1,1-dimethylethyl (2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl)carbamate 
• 103825-24-7 3-amino-1-methyl-2,3,4,5-tetrahydro-1H-1-benzazepin-2-one 

Relevant articles and documents

HETEROCYCLIC AMIDES AS KINASE INHIBITORS

Disclosed are compounds having the formula (I) wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.

Evaluation of a 125I-labelled benzazepinone derived voltage-gated sodium channel blocker for imaging with SPECT

Voltage-gated sodium channels (VGSCs) are a family of transmembrane proteins that mediate fast neurotransmission, and are integral to sustain physiological conditions and higher cognitive functions. Imaging of VGSCs in vivo holds promise as a tool to elucidate operational functions in the brain and to aid the treatment of a wide range of neurological diseases. To assess the suitability of 1-benzazepin-2-one derived VGSC blockers for imaging, we have prepared a 125I-labelled analogue of BNZA and evaluated the tracer in vivo. In an automated patch-clamp assay, a diastereomeric mixture of the non-radioactive compound blocked the Nav1.2 and Nav1.7 VGSC isoforms with IC50 values of 4.1 ± 1.5 μM and 0.25 ± 0.07 μM, respectively. [3H]BTX displacement studies revealed a three-fold difference in affinity between the two diastereomers. Iodo-destannylation of a tin precursor with iodine-125 afforded the two diastereomerically pure tracers, which were used to assess binding to VGSCs in vivo by comparing their tissue distributions in mice. Whilst the results point to a lack of VGSC binding in vivo, SPECT imaging revealed highly localized uptake in the interscapular region, an area typically associated with brown adipose tissue, which in addition to high metabolic stability of the iodinated tracer, demonstrate the potential of 1-benzazepin-2-ones for in vivo imaging.

Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer''s disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer''s disease both prophylactically and therapeutically with such pharmaceutical compositions.

Lactam inhibitors of factor Xa and method

Lactam inhibitors are provided which have the structure including pharmaceutically acceptable salts thereof and all stereoisomers thereof, and prodrug esters thereof, wherein n is 1 to 5; and and R1, R2, R3, R4, R5 , R6, R7, R8, R9, R10, R10a, 1011 and R12 are as defined herein. These compounds are inhibitors of Factor Xa and thus are useful as anticoagulants. A method for treating cardiovascular diseases associated with thromboses is also provided.

Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Reduction of azides to amines or amides with zinc and ammonium chloride as reducing agent

Alkyl azides and acyl azides were reduced to the corresponding amines and amides with zinc and ammonium chloride as reducing agent under mild conditions in good to excellent yield.

MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS

The present application describes monocyclic or bicyclic carbocycles and heterocycles and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

1,3-Disubstituted benzazepines as neuropeptide Y Y1 receptor antagonists

A novel class of potent and selective non-peptide neuropeptide Y (NPY) Y1 receptor antagonists, having benzazepine nuclei, have been designed, synthesized, and evaluated for activity. Through a blind screening we found the compound 1-N-(3-(N' -(tert-butoxycarbonyl)amino)benzyl)-7-methoxy-3-(3)-methylureido)-2,3,4,5-tetrahydro-1H-1-benzazepin-2-one (9: IC50 =1.6 μM). Chemical modifications of 9 gave a potent NPY Y1 antagonist 3-(N-(4-hydroxyphenyl)-N0 -methylguanidino)-1-N-(3-(N'-(tert- butoxycarbonyl)amino)benzyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-2-one (14c: IC50 =43 nM), which had no affnity for NPY Y2 and Y5 receptors. (C) 1999 Elsevier Science Ltd. All rights reserved.